Epilepsy & Seizures

Filter Your Results

 

News

 

Significant Seizure Reduction in Persons With Dravet Syndrome With ZX008 in Phase 3 Trial

Thursday, July 12, 2018—Adjunctive treatment of persons with Dravet syndrom with the investigational compound, low-dose fenfluramine hydrochloride (ZX008; Zogenix, Emeryville, CA), has been shown to …

Epidiolex Approved for Treatment of Dravet and Lennox-Gastaut Syndromes

Tuesday, June 26, 2018—Yesterday, the Food and Drug Administration (FDA) approved cannabidiol (CBD) oral solution (Epidiolex; GW Research, Carlsbad, CA) for the treatment of seizures associated with…

Medtronic Deep Brain Stimulation Clinician Programmer Receives FDA Approval

Wednesday, June 13, 2018—Medtronic announced that the Food and Drug Administration (FDA) had recently approved its Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application.…

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Friday, June 01, 2018—Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regar…

New Type of Vertigo Defined That May Be Treatable

Wednesday, May 23, 2018—Neurologists have defined a new type of vertigo with no known cause (Neurology. 2018:published online May 23). The authors have differentiated this type of vertigo from seriou…

Growing Evidence for Cannabidiol to Treat Lennox Gastaut Syndrome and Dravet Syndrome

Thursday, May 17, 2018—Results of a phase 3 clinical trial comparing adjunctive treatment with cannabidiol (CBD) (Epidiolex; GW Pharmaceuticals/Greenwich Biosciences, Carlsbad, CA) to placebo showed…

Potential New Rescue Therapy for Cluster Seizures, Midazolam Nasal Spray, Acquired by UCB

Wednesday, May 16, 2018—UCB has announced an agreement to acquire the rights to midazolam nasal spray (USL261), intended as a rescue therapy for acute repetitive series (ARS), or cluster seizures. &n…

Premarket Approval for Deep Brain Stimulation for Treatment of Patients with Refractory Partial Onset Seizures

Tuesday, May 01, 2018—The Food and Drug Administration (FDA) has granted premarket approval of deep brain stimulation (DBS) therapy to Medtronic (Dublin, Ireland) for adjunctive treatment to reduce…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC